1 Dicembre Dic 2017 0945 14 days ago

Lancio IMI2 Call 13

Deadline per l'invio delle proposte: 28 Febbraio 2018

Imi

La Innovative Medicine Initiative ha lanciato la IMI2 Call 13.

I topic sono i seguenti:

  • Assessment of the uniqueness of diabetic cardiomyopathy relative to other forms of heart failure using unbiased pheno-mapping approaches
  • Genome-environment interactions in inflammatory skin disease
  • The value of diagnostics to combat antimicrobial resistance by optimising antibiotic use
  • Mitochondrial dysfunction in neurodegeneration
  • Support and coordination action for the projects of the neurodegeneration area of the Innovative Medicines Initiative
  • A sustainable European induced pluripotent stem cell platform
  • Linking digital assessment of mobility to clinical endpoints to drive regulatory acceptance and clinical practice
  • Human tumour microenvironment immunoprofiling
  • CONCEPTION – continuum of evidence from pregnancy exposures, reproductive toxicology and breastfeeding to improve outcomes now
  • Improving the preclinical prediction of adverse effects of pharmaceuticals on the nervous system
  • Translational safety biomarker pipeline (TRANSBIOLINE): enabling development and implementation of novel safety biomarkers in clinical trials and diagnosis of disease
  • Pilot programme on a clinical compound bank for repurposing (This programme includes the following topics: cardiovascular diseases and diabetes; respiratory diseases; neurodegenerative diseases; rare/orphan diseases)

A seguito di una discussione in proposito tra IMI Office, EFPIA e EC, il topic "Development of a Platform for Federated and Privacy-Preserving Machine Learning in Support of Drug Discovery" è stato ritirato dalla Call 13. Tuttavia, esso sarà preso in considerazione per future call.


La deadline per inviare le proposte è il 28 Febbraio 2018.

Clicca qui per il testo orginale.


Inoltre, dallo scorso lunedì 27 novembre, è iniziata la serie di Webinar specifici sui vari Topic della Call 13. E' ancora possibile registrarsi alla maggior parte di essi visitando la pagina ufficiale.

La registrazione è gratuita ma obbligatoria.